Product Description
an aqueous extract from the herb Scutellaria barbata D. Don
Mechanisms of Action: AR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bionovo
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Breast Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00907959 |
BZL-101-003 | P2 |
Unknown status |
Breast Cancer |
2015-01-01 |
2019-03-18 |
Treatments |
|
NCT00454532 |
BZL-101-002 | P2 |
Completed |
Breast Cancer |
2009-12-01 |
2019-03-21 |
Treatments |